The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

The biotech company, which has dual headquarters in Seattle and Houston, adds to a $60 million Series A round it closed last ...

Indapta Therapeutics raises $22.5 million to advance clinical trials for IDP-023, its g-NK cell therapy platform targeting cancer and autoimmune diseases. The funding supports ongoing studies in ...

Current investors RA Capital Management, LP, Leaps by Bayer, the impact investment arm of Bayer AG, Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy ...

Pontifax, Sphera, and VIB. Flamingo has initiated a Phase II trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck ...

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...